Pipeline Pilot was used to determine an estimate of plasma-protein binding for selected analogues. The details of the QSAR model used for prediction are as follows:
S2
or not a compound is likely to be highly bound (≥ 90% bound) to carrier proteins in the blood.
The model outputs the value ADMET_EXT_PPB#Prediction. If true, the compound is predicted to be a binder (≥ 90%). Otherwise, it is predicted to be a weak or non-binder (< 90%).
The outputs in Table S1 defined as follows: § NormalizedProbability (PPB): The standard Laplacian-modified Bayesian score. § Enrichment (PPB#Enrichment): An estimate of enrichment, that is, the increased likelihood (versus random) of this sample being in the "good" category. § EstPGood (PPB#EstPGood): The estimated probability that the sample is in the "good" category, based on an assumed normal distribution of scores within the good and non-good categories. § Prediction: A True/False prediction using the best cutoff value estimated from leave-one-out cross-validation. The cutoff is chosen to minimize the average of the false positive rate and false negative rate. 
